PURAPLY®AM SCIENTIFIC DATA
Discover the antimicrobial effectiveness of PuraPly AM in nonclinical studies.
ANTIMICROBIAL EFFECTIVENESS
In a United States Pharmacopeia Antimicrobial Effectiveness Test, PuraPly AM effectively reduced concentrations of the following microbes at days 7, 14, and 281:
MRSA REDUCTION
Study evaluated the ability of PuraPly AM to reduce biofilm-associated bacteria (MRSA USA300, a clinically virulent strain of Staphylococcus aureus) vs 3 other treatment groups.2
- >98% reduction of MRSA counts compared to baseline
- >96% reduction of MRSA counts vs untreated control on all assessment days
- Largest reduction of MRSA counts vs any of the other treatment groups
- The only treatment to substantially reduce MRSA within 2 days
Watch principal investigator Stephen C. Davis discuss the details of the preliminary study.
SUPPORTING WOUND CLOSURE IN REAL-WORLD STUDIES
See how PuraPly AM supported healing in real-world studies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.
Please refer to the PuraPly AM Instructions for Use for complete prescribing information.
REFERENCES:
- Data on file. USP Antimicrobial Effectiveness Test. Organogenesis Inc.
- Data on file. PDR-0001. Organogenesis Inc.